Changzhou Qianhong Biopharma Co (SZSE:002550) Interest Expense : ¥-1 Mil (TTM As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Changzhou Qianhong Biopharma Co's interest expense for the three months ended in Mar. 2025 was ¥ -0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Changzhou Qianhong Biopharma Co's Operating Income for the three months ended in Mar. 2025 was ¥ 129 Mil. Changzhou Qianhong Biopharma Co's Interest Expense for the three months ended in Mar. 2025 was ¥ -0 Mil. Changzhou Qianhong Biopharma Co's Interest Coverage for the quarter that ended in Mar. 2025 was 712.63. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Changzhou Qianhong Biopharma Co Interest Expense Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Interest Expense Chart

Changzhou Qianhong Biopharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.30

-0.09

-5.19

-5.93

-1.39

Changzhou Qianhong Biopharma Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-0.73	-0.26	-0.19	-0.21	-0.18

Changzhou Qianhong Biopharma Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1 Mil.

Changzhou Qianhong Biopharma Co (SZSE:002550) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Changzhou Qianhong Biopharma Co's Interest Expense for the three months ended in Mar. 2025 was ¥-0 Mil. Its Operating Income for the three months ended in Mar. 2025 was ¥129 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was ¥0 Mil.

Changzhou Qianhong Biopharma Co's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	128.986	/	-0.181
	=	712.63

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Changzhou Qianhong Biopharma Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Changzhou Qianhong Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022

Website

http://www.qhsh.com.cn

Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Executives

Huang Jie	Executives
Wang Ke	Directors, executives
Jiang Wen Qun	Supervisors
Zou Shao Bo	Executives
Wei Li Jun	Executives
Mei Chun Wei	Executives
Zhou Xiang	Directors, executives
Zhao Gang	Director
Ye Hong Ping	Executives
Liu Jun	Director
Fan Yong	Executives
Jiang Jian Ping	Supervisors
Wang Yao Fang	Director
Hai Tao	Directors, executives
Wang Yi	Director

Changzhou Qianhong Biopharma Co Headlines

No Headlines